Ma Y, Li Y, Wen Z, Lai Y, Kamila K, Gao J
Sci Rep. 2024; 14(1):15654.
PMID: 38977698
PMC: 11231291.
DOI: 10.1038/s41598-024-60351-9.
Zhang M, Ali G, Komatsu S, Zhao R, Ji H
Stem Cell Res Ther. 2022; 13(1):111.
PMID: 35313961
PMC: 8935727.
DOI: 10.1186/s13287-022-02793-4.
Pang J, Li G, Qian H, Wu Y, Chen Y
Cell Biol Int. 2022; 46(5):747-754.
PMID: 35066967
PMC: 9305209.
DOI: 10.1002/cbin.11766.
Wu Y, Cai Q, Li W, Cai Z, Liu Y, Li H
Biosci Rep. 2019; 39(8).
PMID: 31350342
PMC: 6692568.
DOI: 10.1042/BSR20190405.
Peixoto C, Dos Santos Gomes F
J Inflamm (Lond). 2015; 12:54.
PMID: 26379476
PMC: 4570643.
DOI: 10.1186/s12950-015-0099-7.
Type II cyclic guanosine monophosphate-dependent protein kinase inhibits epidermal growth factor receptor activation in different cancer cell lines.
Jiang L, Wu M, Wu Y, Lan T, Wang Y, Qian H
Oncol Lett. 2015; 9(6):2781-2786.
PMID: 26137146
PMC: 4473676.
DOI: 10.3892/ol.2015.3067.
Phosphodiesterase sequence variants may predispose to prostate cancer.
de Alexandre R, Horvath A, Szarek E, Manning A, Leal L, Kardauke F
Endocr Relat Cancer. 2015; 22(4):519-30.
PMID: 25979379
PMC: 4499475.
DOI: 10.1530/ERC-15-0134.
The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.
Wronski S
Cent European J Urol. 2014; 67(3):314-8.
PMID: 25247094
PMC: 4165684.
DOI: 10.5173/ceju.2014.03.art20.
Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells.
Jiang L, Chen Y, Sang J, Li Y, Lan T, Wang Y
Biomed Rep. 2014; 1(3):399-404.
PMID: 24648957
PMC: 3917093.
DOI: 10.3892/br.2013.85.
Type II cGMP-dependent protein kinase inhibits epidermal growth factor-induced phosphatidylinositol-3-kinase/Akt signal transduction in gastric cancer cells.
Wu M, Chen Y, Jiang L, Li Y, Lan T, Wang Y
Oncol Lett. 2013; 6(6):1723-1728.
PMID: 24273605
PMC: 3834871.
DOI: 10.3892/ol.2013.1630.
PKG II inhibits EGF/EGFR-induced migration of gastric cancer cells.
Jiang L, Lan T, Chen Y, Sang J, Li Y, Wu M
PLoS One. 2013; 8(4):e61674.
PMID: 23613900
PMC: 3627897.
DOI: 10.1371/journal.pone.0061674.
Endogenous cGMP-dependent protein kinase reverses EGF-induced MAPK/ERK signal transduction through phosphorylation of VASP at Ser239.
Tao Y, Gu Y, Cao Z, Bian X, Lan T, Sang J
Oncol Lett. 2012; 4(5):1104-1108.
PMID: 23162660
PMC: 3499524.
DOI: 10.3892/ol.2012.851.
Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors.
Karami-Tehrani F, Fallahian F, Atri M
Tumour Biol. 2012; 33(6):1927-32.
PMID: 22791569
DOI: 10.1007/s13277-012-0453-9.
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).
VENTURA S, Oliver V, White C, Xie J, Haynes J, Exintaris B
Br J Pharmacol. 2011; 163(5):891-907.
PMID: 21410684
PMC: 3130937.
DOI: 10.1111/j.1476-5381.2011.01332.x.
Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines.
Swartling F, Ferletta M, Kastemar M, Weiss W, Westermark B
Oncogene. 2009; 28(35):3121-31.
PMID: 19543319
PMC: 3030987.
DOI: 10.1038/onc.2009.168.
The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects.
Keswani A, Peyton K, Durante W, Schafer A, Tulis D
J Cardiovasc Pharmacol Ther. 2009; 14(2):116-24.
PMID: 19342499
PMC: 2702762.
DOI: 10.1177/1074248409333266.
Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Porst H, Sandner P, Ulbrich E
Curr Urol Rep. 2008; 9(4):295-301.
PMID: 18765129
DOI: 10.1007/s11934-008-0052-x.
Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia.
Guven E, Balbay M, Mete K, Serefoglu E
Int Urol Nephrol. 2008; 41(2):287-92.
PMID: 18649004
DOI: 10.1007/s11255-008-9423-y.